Qatar

The primary regulatory authority for health products in Qatar is the Ministry of Public Health (MOPH), operating through its Pharmacy and Drug Control Department (PDCD) for pharmaceuticals and the Medical Devices Regulatory Affairs section for devices and diagnostics. The overarching legal framework is established under Law No. 4 of 1983 on the Practice of Human Medicine and its subsequent amendments, alongside Ministerial Decision No. 1 of 2021 and related executive regulations that govern the registration, importation, and commercialization of health products. All medical devices, diagnostics, pharmaceuticals, and digital health solutions intended for the Qatari market must be formally registered or approved by MOPH before they can be marketed, distributed, or procured within the country. The regulatory process generally involves dossier submission through the MOPH online portal, a technical review phase, and where applicable, facility inspections or local conformity assessments.

For pharmaceutical submissions, Qatar broadly follows the Common Technical Document (CTD) format and references international regulatory standards from agencies such as the US FDA, EMA, UK MHRA, and the ICH guidelines. Medical devices are increasingly aligned with Gulf Cooperation Council (GCC) Standardization Organization (GSO) requirements and international frameworks including ISO 13485 and CE marking or FDA 510(k) clearance as reference benchmarks. A local authorized representative or licensed commercial agent registered in Qatar is mandatory for all foreign manufacturers seeking market authorization. Digital health and software as a medical device (SaMD) is an emerging regulatory area, with MOPH progressively developing guidance frameworks in line with global best practices. Qatar has also undertaken regulatory modernization efforts as part of its National Health Strategy 2018-2022 and its successor framework, aiming to streamline review timelines, introduce electronic submission systems, and foster greater alignment with GCC mutual recognition procedures.

Public procurement of health products in Qatar is highly centralized and primarily driven by Hamad Medical Corporation (HMC), the state-owned entity responsible for operating the main network of public hospitals and specialty centers. The Primary Health Care Corporation (PHCC) manages procurement for community and primary care facilities. Both entities operate under the oversight of MOPH and are subject to the national public tendering framework governed by Law No. 24 of 2015 on Public Tenders and Auctions, which requires competitive bidding processes for contracts above defined thresholds. The Government Tenders and Auctions Regulatory Authority (IATAA) provides broader procurement oversight. HMC issues periodic tenders and annual procurement cycles for pharmaceuticals, devices, diagnostics, and consumables, and suppliers must hold valid MOPH registration and meet local agent requirements to participate. Framework agreements and direct procurement may be used for urgent or sole-source situations, particularly for innovative or specialized products.

The private healthcare sector in Qatar is substantial and growing, comprising hospitals, polyclinics, and specialty clinics operated by local and international providers, all of which procure independently through licensed local distributors and agents. Qatar does not rely significantly on multilateral donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, or USAID, given its high-income status, though the country does engage with international bodies for public health programs and emergency preparedness. Qatar has pursued local manufacturing and self-sufficiency goals as part of its National Vision 2030, with incentives directed at attracting pharmaceutical and medtech manufacturing investment to the country, including potential preferential treatment in public tender evaluations for locally manufactured or assembled products. Companies seeking sustained market access are encouraged to explore partnerships with Qatari entities, technology transfer arrangements, or local manufacturing collaborations to align with these strategic priorities.